- Home
- HPAI vs RCEL Comparison
HPAI vs RCEL Comparison
Compare HPAI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- RCEL
- Stock Information
- Founded
- HPAI 2023
- RCEL N/A
- Country
- HPAI Singapore
- RCEL United States
- Employees
- HPAI N/A
- RCEL N/A
- Industry
- HPAI
- RCEL Medical/Dental Instruments
- Sector
- HPAI
- RCEL Health Care
- Exchange
- HPAI NYSE
- RCEL Nasdaq
- Market Cap
- HPAI 221.3M
- RCEL 227.5M
- IPO Year
- HPAI N/A
- RCEL N/A
- Fundamental
- Price
- HPAI $5.00
- RCEL $9.21
- Analyst Decision
- HPAI
- RCEL Strong Buy
- Analyst Count
- HPAI 0
- RCEL 4
- Target Price
- HPAI N/A
- RCEL $17.25
- AVG Volume (30 Days)
- HPAI 39.2K
- RCEL 201.7K
- Earning Date
- HPAI 03-31-2025
- RCEL 05-08-2025
- Dividend Yield
- HPAI N/A
- RCEL N/A
- EPS Growth
- HPAI N/A
- RCEL N/A
- EPS
- HPAI 0.06
- RCEL N/A
- Revenue
- HPAI $31,475,664.00
- RCEL $64,251,000.00
- Revenue This Year
- HPAI N/A
- RCEL $62.33
- Revenue Next Year
- HPAI N/A
- RCEL $30.59
- P/E Ratio
- HPAI $88.84
- RCEL N/A
- Revenue Growth
- HPAI 47.72
- RCEL 28.14
- 52 Week Low
- HPAI $3.07
- RCEL $6.90
- 52 Week High
- HPAI $14.74
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- RCEL 56.76
- Support Level
- HPAI N/A
- RCEL $8.15
- Resistance Level
- HPAI N/A
- RCEL $9.36
- Average True Range (ATR)
- HPAI 0.00
- RCEL 0.67
- MACD
- HPAI 0.00
- RCEL 0.15
- Stochastic Oscillator
- HPAI 0.00
- RCEL 93.90
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.